

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed. The patent has been licensed to an ar

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Lipson 1



Section 1. Identifying Inform			
Identifying Inform	ation		
Given Name (First Name) David	2. Surname (Last Name) Lipson		3. Date 01-May-2020
4. Are you the corresponding author?	✓ Yes No		
5. Manuscript Title Response Letter			
6. Manuscript Identifying Number (if you kr Blue-202004-1399LE	now it)		
Section 2. The Work Under Co	onsideration for Public	ation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intered If yes, please fill out the appropriate info Excess rows can be removed by pressing	s but not limited to grants, da est? Yes No ormation below. If you hav	ta monitoring board, study	y design, manuscript preparation,
Name of Institution/Company	Grant	n-Financial Other?	Comments
GlaxoSmithKline		☐ ✓ Th	nis study was funded by GSK
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	ibed in the instructions. Us port relationships that wer est?	se one line for each entit	ry; add as many lines as you need by
Name of Entity	Grant	n-Financial Other?	Comments
GlaxoSmithKline		✓ Em	nployee of GSK
GlaxoSmithKline		✓ Sh	nares/options held in GSK

Lipson 2



Section 4. Intellectual Property Patents & Copyrights						
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume						
Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Statement						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Lipson reports other from GlaxoSmithKline, during the conduct of the study; other from GlaxoSmithKline, other from GlaxoSmithKline, outside the submitted work; .						

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Lipson 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Info			
Identifying Info	rmation		
1. Given Name (First Name) Mark	2. Surname (Last Name) Dransfield	3. Date 01-May-2020	_
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name David Lipson	
5. Manuscript Title Response Letter			
6. Manuscript Identifying Number (if you Blue-202004-1399LE	ı know it)		
Section 2. The Work Under	Consideration for Public	cation	
	ing but not limited to grants, da	n a third party (government, commercial, private foundation, etc.) that a monitoring board, study design, manuscript preparation,	for
If yes, please fill out the appropriate i Excess rows can be removed by press	nformation below. If you hav	ve more than one entity press the "ADD" button to add a ro	w.
Name of Institution/Company	Grant	n-Financial Other? Comments	
GlaxoSmithKline		This study was funded by GSK	
Costion 2			
Section 3. Relevant financi	al activities outside the s	submitted work.	
of compensation) with entities as des	scribed in the instructions. Us report relationships that wer erest? Yes No	nether you have financial relationships (regardless of amour se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .	
Name of Entity	Grant	n-Financial Other? Comments	
Department of Defense	✓		
Boehringer Ingelheim		Consulting and contracted clinical trials	
GlaxoSmithKline		Consulting and contracted clinical	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Novartis				✓	Contracted clinical trials	
AstraZeneca		✓		√	Consulting and contracted clinical trials	
Yungjin				✓	Contracted clinical trials	
PneumRx/BTG		✓		✓	Consulting and contracted clinical trials	
Pulmonx				✓	Contracted clinical trials	
Genentech		✓			Consulting	
Boston Scientific				✓	Contracted clinical trials	
Quark Pharmaceuticals		✓			Consulting	
NIH	✓					
Mereo		✓			Consulting	
American Lung Association	✓					
NIH	\checkmark					
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Dransfield reports other from GlaxoSmithKline, during the conduct of the study; grants from Department of Defense, personal fees and other from Boehringer Ingelheim, personal fees and other from GlaxoSmithKline, other from Novartis, personal fees and other from AstraZeneca, other from Yungjin, personal fees and other from PneumRx/BTG, other from Pulmonx, personal fees from Genentech, other from Boston Scientific, personal fees from Quark Pharmaceuticals, grants from NIH, personal fees from Mereo, grants from American Lung Association, grants from NIH, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



1. Given Name (First Name) MeiLan 2. Surname (Last Name) Han 3. Date 01-May-2020 4. Are you the corresponding author? Yes No Corresponding Author's Name David Lipson 5. Manuscript Title Response Letter 6. Manuscript Identifying Number (if you know it) Blue-202004-1399LE	
David Lipson 5. Manuscript Title Response Letter 6. Manuscript Identifying Number (if you know it)	
Response Letter 6. Manuscript Identifying Number (if you know it)	
• • • • • • • • • • • • • • • • • • • •	
Section 2. The Work Under Consideration for Publication	
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation statistical analysis, etc.)?	
Are there any relevant conflicts of interest? ✓ Yes No	
If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add Excess rows can be removed by pressing the "X" button.	l a row.
Name of Institution/Company Grant Personal Fees Non-Financial Support Comments	
GlaxoSmithKline	
Section 3. Relevant financial activities outside the submitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of a of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you not clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below.	ed by
Name of Entity Grant? Personal Fees? Support? Other? Comments	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Novartis				✓	Research support	
Sunovion				✓	Research support	
Mylan		\checkmark				
Section 4.						
Intellectual Propert	y Pate	ents & Co _l	oyrights			
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes V No	
Section 5. Relationships not c	overed	above				
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of	
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	pw):	
✓ No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest	
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					•	ents.
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.		omatically (generate a disclos	sure state	ement, which will appear in the box	
Dr. Han reports other from GlaxoSmithK fees from Boehringer Ingelheim, person fees from Mylan, outside the submitted	al fees fro					



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.